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Human embryonic stem cell derived astrocytes
mediate non-cell-autonomous neuroprotection
through endogenous and drug-induced mechanisms
K Gupta1,2,3,4,5, R Patani3,7, P Baxter2,7, A Serio1,4,5, D Story1, T Tsujita6, JD Hayes6, RA Pedersen3, GE Hardingham*,2
and S Chandran*,1,4,5
The glial environment is an important determinant of neuronal health in experimental models of neurodegeneration. Specifically,
astrocytes have been shown, dependent on context, to be both injurious and protective. Human pluripotent stem cells offer a
powerful new system to improve our understanding of the mechanisms underlying astrocyte-mediated neuroprotection. Here,
we describe a human embryonic stem cell (HESC)-based system to assess the scope and mechanism of human astrocyte-
mediated neuroprotection. We first report the generation of enriched and functional HESC-derived astrocytes, by combining
BMP-mediated Smad and LIF-mediated JAK-STAT signalling. These astrocytes promote the protection of HESC-derived neurons
against oxidative insults. Moreover, their neuroprotective capacity can be greatly enhanced by treatment with the nuclear factor-
erythroid 2-related factor 2 (Nrf2)-activating triterpenoid 1[2-Cyano-3,12-dioxool-eana-1,9(11)-dien-28-oyl] trifluoroethylamide
(CDDOTFEA). Activation of the transcription factor Nrf2 in human astrocytes by CDDOTFEA treatment induced expression of the
glutamate-cysteine ligase (GCL) catalytic subunit, leading to enhanced GCL activity and glutathione production, and strong
neuroprotection against H2O2. This enhanced neuroprotection was found to be dependent on astrocytic GCL activity, unlike the
basal neuroprotection afforded by untreated astrocytes. Direct treatment of HESC-derived neurons with CDDOTFEA elicited no
induction of Nrf2 target genes, nor any neuroprotection. Thus, human astrocytes can mediate neuroprotection through
glutathione-dependent and glutathione-independent mechanisms, and represent a therapeutic target for human disorders
associated with neuronal oxidative stress.
Cell Death and Differentiation (2012) 19, 779–787; doi:10.1038/cdd.2011.154; published online 18 November 2011
Neurodegenerative diseases such as Alzheimer’s disease,
Parkinson’s disease, and amyotrophic lateral sclerosis (ALS)
are untreatable conditions that collectively represent a major
healthcare burden. Improved understanding of the biology of
these diseases is required in order to develop neuroprotective
and ultimately reparative treatments. Until recently, neurode-
generative diseases have been largely regarded as exclu-
sively neuronal disorders. However, recent findings have
challenged this concept, implicating non-cell-autonomous
mechanisms of neurodegeneration mediated by astrocytes
in acute and chronic disorders.1,2
The role of astrocytes in influencing neuronal viability has
primarily been characterised in rodent systems. Advances in
human stem cell biology now allow the modelling of human
astrocyte–neuronal interaction under physiological and injury
paradigms. Although there are robust platforms for the
generation of neural stem cells and functional neurons, the
generation of enriched and functional human astrocytes is
comparatively understudied.3,4 While our understanding of
astrogliogenesis remains incomplete, it is well established
that neurogenesis precedes gliogenesis and this in turn is
reflected in differential temporal phenotypic potential of neural
precursor cells (NPCs); young precursors are neuron re-
stricted while aged precursors are glial competent.5–7 In
addition to poorly understood epigenetic changes that control
temporal competence to astrogliogenesis, extrinsic signals
are important determinants of astrocyte fate, including the
JAK-STAT pathway activated by cytokines such as LIF,
CNTF, and cardiotrophin 1 as well as BMP signalling acting
through the Smad transcription factor family.8,9 Synergistic
interaction between these two signalling pathways raises the
possibility that dual activation of STAT and BMP signalling will
promote astrogliogenesis from human ES-derived neural
precursors.10
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While the underlying cause of individual neurodegenerative
diseases is unknown, multiple lines of evidence implicate
oxidative stress in disease pathogenesis.11 The support of
neuronal antioxidant defences by astrocytes represents a
key neuroprotective role and its manipulation represents an
emerging therapeutic strategy for a range of acute and chro-
nic neurological disorders associated with oxidative stress.12
One attractive target is the transcription factor nuclear factor-
erythroid 2-related factor 2 (Nrf2), a master regulator of
antioxidant defences and drug-metabolising enzymes. The
binding of Nrf2 to a cis-acting DNA promoter sequence called
the antioxidant response element (ARE), allows trans-activa-
tion of a group of genes that includes key components of the
glutathione antioxidant system.13 Under normal conditions,
Nrf2 is bound in the cytoplasm by Kelch-like ECH-associated
protein 1 (Keap1) and targeted for proteasomal degrada-
tion.14 However, the Keap1-dependent turnover of Nrf2 can
be inhibited by oxidative stress and a variety of small
molecules, leading to an accumulation of Nrf2 whereupon it
accumulates in the nucleus and activates ARE-driven genes.
Activation of Nrf2 by mild oxidative stress in astrocytes
contributes to neuroprotective ischaemic preconditioning,15
although other mechanisms exist.16 Furthermore, pharmaco-
logical activation of astrocytic Nrf2, or overexpression of Nrf2
in astrocytes, confers a neuroprotective response in rodent
models of Parkinson’s disease, and ALS.17–19 The mech-
anism behind this non-cell-autonomous neuroprotection is
thought to be through the upregulation of astrocytic glu-
tathione biosynthesis and secretion, breakdown products
of which are used by the neurons to support their own
glutathione levels.18 Noting inter-species functional differe-
nces, the relevance of these rodent-based astrocyte-mediated
neuroprotective effects to human experimental systems is
unknown.20
Here, we describe a novel protocol for generating highly
enriched, functional astrocytes derived from human embryo-
nic stem cells (HESCs), using a combination of develop-
mental cues. By generating a separate population of neurons
derived from the same HESC line, we establish a human-
centred platform for assessing the neuroprotective properties
of compounds when administered either directly to neurons,
or in triggering a non-cell-autonomous neuroprotective res-
ponse in astrocytes. As proof-of-concept, we demonstrate a
key capacity for human astrocytes to mediate neuroprotective
responses, including those triggered by a small molecule
activator of Nrf2 that can only act in this non-cell-autonomous
manner.
Results
Generation of enriched and functional astrocytes from
human ES cells. In order to establish a platform to study
astrocyte–neuronal interactions, we first generated a stable
human neural precursor cell (hNPC) population. Using establi-
shed protocols, HESC neural aggregates were first derived.21
At day 8, neural aggregates were mechanically dissociated
and plated as an adherent monolayer in defined conditions
on gelatin, selecting for neural rosette-like structures at each
passage.22 By day 30, a near homogeneous population of
hNPCs were obtained that were both nestin and 3CB2
positive (93.9±1.0% and 82.7±2.1%, respectively; Figures
1a and b) and had a bipolar morphology consistent with a
radial glial identity.
In order to generate astroglia, hNPCs were further
propagated until day 55 when they expressed, along with
nestin, and key receptors and downstream signalling effectors
for astrogliogenesis. These included BMP and LIF receptors
and, SMAD1 and STAT3, by RT-PCR (Figure 1c). Having
previously shown that BMP4 promotes astrogliogenesis,5 we
sought to refine this process in order to obtain more enriched
astroglial populations for further enrichment. We system-
atically tested the efficacy of BMP4 alone and in combination
with LIF and BMP2, which have been shown previously to
promote astroglial commitment.9,10 Astroglial specification
was screened by measuring differential gene expression of
brain lipid binding protein (BLBP), a neural precursor marker,
and glutamine synthetase (GS), an astrocyte-expressed
enzyme required for production of glutathione and glutamate
recycling in neurotransmission. Gene expression analysis
revealed downregulation of BLBP and upregulation of GS with
all treatment groups relative to control (Po0.05). The com-
bination of BMP4 and LIF resulted in the greatest change in
gene expression (Figure 1d). Quantitative immunohistochem-
istry was next undertaken with astrocyte differentiation deter-
mined by downregulation of nestin and concomitant upregula-
tion of GFAP staining, along with a change in morphology from
bipolar to stellate. Although all treatment groups increased
the numbers of cells with GFAP staining, the combination
of BMP4 and LIF resulted in the greatest upregulation
(88.4±2.0% versus control 35.8±3.6%; Figures 1e–h).
Prolonged exposure (12 days) to BMP4 and LIF increased
GFAP-positive staining to 95.7±3.1%. Furthermore, GFAP-
positive astrocytes derived by BMP4/LIF co-treatment also
stained positive for other markers of astrocyte differentiation;
aquaporin 4 (79.4±1.0%) (Figure 1i), S100b (90.1±2.0%)
(Figure 1j), and EAAT1 (89.5±3.2%) (Figure 1k). A defining
physiological role of astrocytes is glutamate uptake mediated
by Naþ -dependent channels that include members of the
excitatory amino-acid transporter family EAAT1 and EAAT2.23
Radiolabelled glutamate uptake assays revealed negligible
hNPC uptake in contrast to robust Naþ -dependent glutamate
uptake by BMP4/LIF-derived astrocytes consistent with
astrocyte function (Figure 1l). Combined BMP4/LIF treatment
was therefore used for subsequent functional and neuro-
protection experiments.
Human astrocytes attenuate oxidative neuronal injury.
Having established functional hNPC-derived astrocytes, we
next generated an enriched population of neurons from
HESCs in order to examine human astrocyte–neuronal inter-
action in the context of oxidative stress. Neural stem cells
were generated from H9 HESCs as described by Koch
et al.22; following differentiation for 10 days 95.5±1.4% were
TuJ1 positive upon immunostaining (Figure 2a). Studies
predominantly based in rodent systems have shown that
astrocytes can release soluble factors that support the growth,
development, and survival of neurons, and so astrocyte-
conditioned medium (ACM) can be neuroprotective.24 We
therefore sought to determine whether medium conditioned
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Figure 1 Derivation of astrocytes from HESCs. hNPC markers were quantified by immunohistochemistry for (a) nestin and (b) 3CB2-positive staining (scale bar, 100mm)
and analysed for (c) the presence of BMP and LIF signalling mediators by RT-PCR. hNPCs were treated with BMP2, BMP4, and LIF in combination and (d) mRNA expression
of BLBP and GS analysed by quantitative real-time PCR, normalised to GAPDH. *Po0.05 ANOVA, Newman–Keuls post-test (n¼ 3). Astrocyte yield was confirmed by (e–h)
quantification of GFAP-positive immunostaining (scale bar, 100mm), and (i–k) the presence of astrocyte markers AQP4, S100b and EAAT1 was examined to confirm
astrocyte identity (scale bar, 50 mm). *Po0.05 ANOVA, Newman–Keuls post-test (n¼ 3). (l) Astrocyte function was confirmed by examining sodium-dependent glutamate
uptake. *Po0.05 paired t-test (n¼ 3)
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by HESC-derived astrocytes could exert a neuroprotec-
tive effect on HESC-derived neurons, using H2O2 to model
an oxidative insult (Figures 2b and c). Cell death in response
to H2O2 treatment was quantified with the CellTiter-glo
assay and confirmed by quantitative immunohistochemistry
determining activated caspase-3/TuJ1 positive co-staining
(Figures 2d–f). Addition of ACM resulted in a significant
neuroprotective effect against H2O2-induced injury, compa-
red with unconditioned medium (31.0±1.8% loss of viability
compared with control: 41.4±1.4% loss of viability; Figure 2c,
Po0.05). Immunofluorescent analysis of caspase-3 activa-
tion revealed similar results: treatment of neurons with 50 mM
H2O2 caused an increase of active caspase-3-positive
neurons from 1.5±0.7% to 43.6±5.0%; however, the pre-
sence of ACM reduced the level of H2O2-induced caspase-3
activation to 30.2±2.5% (Figures 2d–f). Thus, human
astrocytes are able to protect neurons against oxidative
insults through the release of soluble factors.
CDDOTFEA treatment reveals glutathione-dependent
and glutathione-independent mechanisms for astrocyte-
mediated neuroprotection. Nrf2 activation in rodent
astrocytes can confer increased antioxidant capacity on
neurons by mechanisms that include enhanced glutathione
biosynthesis and secretion.15,18,19 There is also growing
evidence for Nrf2-activating synthetic triterpenoids as poten-
tial therapeutic agents in experimental models of neuro-
degenerative diseases associated with oxidative stress.25 To
test their relevance to human systems, we examined whether
the triterpenoid CDDOTFEA26 could induce Nrf2 target gene
expression in human astrocytes and whether this leads to an
enhanced neuroprotective response.
We first studied the expression of two Nrf2 target genes,
NFE2L2 (encoding Nrf2 itself) and GCLC (the glutamate-
cysteine ligase catalytic subunit). The GCLC gene encodes
the catalytic subunit of GCL, which performs the rate-limiting
step in glutathione biosynthesis. Compared with neurons,
Figure 2 ACM protects neurons from peroxidative injury. Highly enriched HESC-derived neurons demonstrated (a) 495% TuJ1-positive immunostaining (scale bar,
100mm). (b) HESC-derived astrocyte cultures were used to condition minimal medium over 24 h. (c) Enriched HESC-derived neuronal cultures were treated with H2O2
(50mM) for 6 h in minimal medium and ACM, and neuronal viability quantified. (d–f) Representative TuJ1 and activated caspase-3 co-staining (scale bar, 50 mm). *Po0.05
ANOVA, Newman–Keuls post-test (n¼ 3)
HESC-derived astrocytes mediate non-cell-autonomous neuroprotection
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astrocytes showed far higher basal levels of both NFE2L2 and
GCLC, indicative of a higher basal Nrf2 activity (Figure 3a).
Moreover, these levels were further increased by treatment of
astrocytes with CDDOTFEA (Figure 3a). Consistent with an
upregulation in GCLC expression, cell-free extracts taken
from CDDOTFEA-treated astrocytes exhibited elevated levels
of GCL enzyme activity (24 h, 46.8±18% greater than control)
(Figure 3b). To determine whether this in turn translated to
increased glutathione levels in astrocytes, we assessed
intracellular glutathione content using an assay based on
monochlorobimane (MCB). MCB is non-fluorescent in its
native state and becomes fluorescent upon conjugation to
glutathione in the cell.27 CDDOTFEA treatment of astrocytes
resulted in a substantial increase in glutathione levels (6 h,
34.7±13.8% greater than control, Po0.05; 24 h, 54.4±
17.7% greater than control, Po0.05; Figure 3c) that was
completely blocked by co-treatment with the GCL inhibitor
buthionine sulfoximine (BSO) (CDDOTFEA/BSO: 37.3±
14.5% at 6 h, 65.8±6.3% at 24 h; BSO: 16.1±8.4% at
6 h, 63.0±3.8% at 24 h; Figure 3c). Thus, CDDOTFEA
treatment of human astrocytes upregulates Nrf2 target gene
expression, GCL enzyme activity, and glutathione production,
raising the possibility that this influences their neuroprotective
capacity.
Before investigating the capacity of CDDOTFEA to boost
astrocyte-mediated neuroprotection in our human system, we
first sought to establish its dependence on Nrf2 using cultures
derived from wild-type and Nrf2-deficient mice. We first
established that CDDOTFEA-mediated neuroprotection re-
quired the presence of astrocytes (Figure 4a). CDDOTFEA
treatment protected neurons against H2O2-induced death in
mixedNrf2þ /þ cortical cultures (90% NeuN-positive neurons,
10% GFAP-positive astrocytes;15,25 however, no protection
was observed in astrocyte-free Nrf2þ /þ neuronal cultures
(Figure 4a). We then investigated the Nrf2 dependence of
CDDOTFEA-induced neuroprotection (Figure 4b). We found
that CDDOTFEA-induced neuroprotection of mixed cultures
was dramatically diminished in Nrf2/ mixed cultures,
compared with those from Nrf2þ /þ mice. These data indicate
that CDDOTFEA-mediated neuroprotection is indeed mediated
through its effects on the Nrf2 pathway (Figure 4b).
To investigate whether CDDOTFEA treatment of human
astrocytes can promote protection of human neurons, astro-
cytes were treated with or without CDDOTFEA for 6 h, in the
presence or absence of BSO, after which all drugs were
washed out and fresh medium added for the astrocytes to
condition for 24 h (Figure 4c). Medium conditioned by
CDDOTFEA-treated astrocytes was significantly more neuro-
protective against oxidative injury than medium conditioned
by untreated astrocytes as determined by viability assay and
active caspase-3 immunohistochemistry (Figures 4d–g). The
enhanced protective response induced by CDDOTFEA was
blocked if GCL activity was inhibited by co-treatment with BSO
(Figures 4d and g), implicating enhanced astrocytic GCL
activity and glutathione production as the mechanism under-
lying protection conferred by CDDOTFEA treatment in contrast
to a glutathione-independent protective effect mediated by
basal untreated astrocytes (Figure 4d). We next examined
whether CDDOTFEA treatment of neurons alone was also pro-
tective against oxidative injury. Unlike astrocytes, CDDOTFEA
treatment of neurons failed to induceNFE2L2 orGCLCmRNA
expression (1.25±0.2, 1.23±0.1 fold change) (Figure 4h),
and importantly conferred no significant protective effect
against H2O2-induced oxidative injury, at a range of concen-
trations (Figure 4i). These findings reveal that CDDOTFEA can
only exert its human neuroprotective effects non-cell-auton-
omously via Nrf2 activation and glutathione production in
astrocytes. Thus, basal and CDDOTFEA-induced astrocyte-
mediated neuroprotection against oxidative injury involves
distinct glutathione-dependent and glutathione-independent
mechanisms.
Discussion
The role of the glial environment in modulating health, injury,
and protection of neurons is becoming increasingly well
recognised.1,28 In order to further understand the relevance
of glial signalling to human neuronal injury, there is a need to
first establish appropriate human systems of glial–neuronal
interaction. This study highlights the utility of HESCs for
in-vitro human glial–neuronal modelling and demonstrates
generation of highly enriched functional human astrocytes
that promote survival of neurons following oxidative injury. In
addition, we find that human astrocytic neuroprotective res-
ponses involve multiple mechanisms and can be manipulated
by small molecules.
Previous studies have focussed predominantly on neuronal
differentiation of HESCs with some modelling of isolated
neuronal injury.1,2 In contrast, the study of functional HESC-
derived astrocytes is limited with negligible investigation of
Figure 3 Astrocytes upregulate NRF2 pathway with CDDOTFEA treatment. (a) mRNA expression of NFE2L2 and GCLC were examined by quantitative real-time PCR,
normalised to GAPDH. Cell types examined included enriched human neuron and astrocyte cultures, and human astrocyte cultures treated with CDDOTFEA (250 nM) for 6 h.
*Po0.05, **Po0.01 paired t-test (n¼ 3). (b) GCL enzyme activity was examined in enriched human astrocyte cultures treated with CDDOTFEA (250 nM) for 6 h. *Po0.05
paired t-test (n¼ 3). (c) Enriched human astrocytes were treated with CDDOTFEA (250 nM), BSO (200mM), and CDDOTFEA þ BSO for 6 h and 24 h, and intracellular GSH
quantified by the MCB assay. *Po0.05 ANOVA, Newman–Keuls post-test (n¼ 3)
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human glial–neuronal interaction. Astrocytic differentiation is
determined temporally by intrinsic mechanisms5 and exogen-
ous factors, including BMP4 and LIF;9 LIF and other members
of the IL-6 cytokine family have been shown to synergi-
stically drive astroglial differentiation in conjunction with
BMPs, STAT3, and SMAD1 converging upon CBP/p300,
Figure 4 CDDOTFEA drug treatment is neuroprotective by a GSH-dependent, astrocyte-mediated mechanism. (a) CDDOTFEA-induced neuroprotection requires the
presence of astrocytes. Mixed mouse cortical cultures (90% NeuNþ neurons, 10% GFAPþ astrocytes) or astrocyte-free mouse neuronal cultures (498% NeuNþ ,
o0.2% GFAPþ ) were treated with CDDOTFEA (100 nM) for 24 h, before treatment with H2O2 (100mM) for a further 24 h, after which cultures were fixed and levels of cell
death assessed. *Po0.05 paired t-test (n¼ 4). (b) CDDOTFEA-induced neuroprotection is Nrf2-dependent. CDDOTFEA-induced neuroprotection in mixed Nrf2þ /þ or Nrf2/
mouse cortical cultures was studied using the same protocols as (a). *Po0.05 paired t-test (n¼ 4). (c) Enriched human astrocyte cultures were treated with CDDOTFEA
(250 nM)±BSO (200mM) for 6 h, the drug washed out, and fresh minimal medium replaced for conditioning over 24 h. ACM was derived as previously and supplemented with
H2O2. (d) Human neuronal viability was assessed upon treatment with H2O2 (50mM) for 6 h, in ACM derived from untreated and CDDO
TFEA-treated enriched astrocytes. BSO
co-treatment was used to block GCL activity, demonstrating GCL-dependent and -independent neuroprotective effects of ACM. (e–g) Representative TuJ1 and activated
caspase-3 co-staining (scale bar, 50mm). *Po0.05 ANOVA, Newman–Keuls post-test (n¼ 3). (h) Human neuronal expression of NFE2L2 and GCLC mRNA with 6 h
CDDOTFEA (250 nM) treatment were examined by quantitative real-time PCR. (i) The effect of treatment with CDDOTFEA (250 nM) for 24 h on human neuronal viability was
determined over a range of H2O2 concentrations (0–200mM, 6 h). *Po0.05 paired t-test (n¼ 3)
HESC-derived astrocytes mediate non-cell-autonomous neuroprotection
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respectively.10 We extend our previous observations5 and
demonstrate scaleable generation of highly enriched astro-
cytes from HESCs through BMP4 and LIF application to late
neural precursors. Accurate glial–neuronal disease modelling
requires prior demonstration of function. While this study has
been in preparation, Krencik et al.4 described the use of LIF/
CNTF-mediated astrocyte differentiation from HESC-derived
neural aggregates over 180 days, observing expression of
astrocyte-specific markers including GFAP/S100b and gluta-
mate uptake among other characterisation. We demonstrate
the use of co-operative BMP4/LIF signalling for similar levels
of astrocyte enrichment over a considerably shorter time
course. The astrocytes generated in this study express a
range of astrocyte markers; GFAP, AQP4, S100b, and
EAAT1 and also crucially demonstrate functional glutamate
uptake capacity.
There is growing evidence that astrocyte behaviour is
dynamic, potentially either beneficial or detrimental for
neuronal survival. Accumulating in-vivo evidence highlights
a powerful neuroprotective effect of astrocytes.29,30 We have
shown previously in a rodent transgenic model of human
P301S t-mediated neurodegeneration, that age-related loss
of neurons is reversed by astroglial transplantation.29 Other
groups have shown similarly that astrocyte transplantation
in a rodent transgenic model of ALS expressing human
SOD1*G37R attenuated motor neuron loss and motor
decline.30 Here, we demonstrate that HESC-derived astro-
cytes were able to protect neurons from oxidative injury by
soluble factors, through a mechanism independent of de novo
glutathione synthesis. Astrocytic supply of glutathione to
neurons has been implicated as a key mediator of neuronal
antioxidant defence;18,31 baseline secretion of glutathione
remains a potential neuroprotective mechanism as the
duration of BSO treatment blocked de novo glutathione
synthesis and did not fully deplete astrocytes of intracellular
glutathione. Other soluble factor-mediated neuroprotective
mechanisms include secretion of neurotrophic factors such as
GDNF and IGF-1.29,32
Oxidative stress is particularly prevalent in neurodegen-
erative injury11 and, as astrocytes are central to antioxidant
defence in the CNS,33 modulation of astrocyte antioxidant
abilities has been considered a potential therapeutic target in
altering the clinical course of such disorders.12,34 To this end,
activators of Nrf2 have received considerable atten-
tion.12,15,17,19,35 Nrf2 modulation in astrocytes has a key role,
abating neurological injury and disease progression in mouse
models of ALS and Parkinson’s disease in a glutathione-
dependent manner.17,19 We recently identified activation of
astrocytic Nrf2 as a contributor to endogenous neuroprotec-
tive responses in the context of ischaemic preconditioning.15
The synthetic oleanane class of triterpenoids, which includes
CDDO analogues, presents a promising drug treatment in
multiple pathologies, due to their ability to modulate the
activity of Nrf2.25 This study demonstrates that CDDOTFEA is
capable of inducing strong neuroprotective responses in
human astrocytes via a glutathione-dependent mechanism.
Strikingly, human neurons derived from the same HESC line
were completely incapable of responding to CDDOTFEA either
in terms of activation of Nrf2 target genes, or by eliciting a
neuroprotective effect. The reason behind this is unclear but
may be due to low levels of NFE2L2 mRNA (which encodes
Nrf2) in neurons (Figure 3a). However, it is consistent with the
observation from mixed rodent cultures that astrocytes
represent the major locus for Nrf2 activation, induced both
by small molecules and by oxidative stress.15,18
Non-cell-autonomous neuroprotection, as shown in our
study, has widespread and fundamental implications for
human-based drug discovery and screening of novel neuro-
protective agents. Specifically, our findings suggest that
screens focussing solely on the direct effect of compounds
on isolated neurons will overlook potentially important
neuroprotective activities that act via astrocytes or other
non-neuronal cells. To conclude, these studies provide
important proof-of-concept that human stem cell derived
neural derivatives can be used effectively to model neuron–
astrocyte interactions and investigate their mechanism. In
the endeavour for clinically translatable interventions that
may abate the course of neurodegenerative disorders, a key
step in translation is the development of human in-vitro
platforms, for both disease modelling and drug screening.
HESC-based platforms overcome the issues of species-
specific drug responses and transcriptional changes, and
provide an important benchmark platform for studies using
patient-specific pluripotent lines and clinical translation.
Materials and Methods
ES culture and neuralisation. The HESC lines H9 and HUES9 (Harvard
University, Cambridge, MA, USA) were cultured and passaged regularly on a feeder
layer of irradiated mouse embryonic fibroblasts, and neuralised by established
protocols;21 In order to derive adherent hNPCs, HESC-derived neurospheres were
dissociated and underwent selective propagation as an adherent monolayer on
gelatin, in chemically defined medium36 supplemented with 20 ng/ml human FGF-2,
heparin 5 mg/ml and 20 ng/ml human EGF, with 2-day complete medium changes.
hNPCs were propagated for 2 months before astroglial differentiation. For astroglial
differentiation, coverslips were coated with Matrigel (BD Biosciences, Oxford, UK)
for 1 h, diluted 1 : 30 in Dulbecco’s Modified Eagle’s Medium (DMEM). Confluent
hNPCs were enzymatically dissociated with Accutase and plated in basic plating
medium (BPM) composed of 4.5 g/l glucose DMEM (Invitrogen, Carlsbad, CA, USA)
supplemented with 2% B27 supplement minus antioxidants (Invitrogen) and 1%
penicillin-streptomycin. BPM was modified for each plating condition with BMP2 and
BMP4 (R&D, Abingdon, UK) at final concentrations of 10 ng/ml, and LIF (Sigma,
St. Louis, MO, USA) at final concentrations of 20 ng/ml. Differentiating astrocytes
received full media changes with factor-supplemented BPM every 2 days. Neurons
underwent differentiation for 10 days in Neurobasal medium, supplemented with
2% B27 supplement minus antioxidants, 1% Glutamax (Gibco, Carlsbad, CA, USA),
1% non-essential amino acids, DAPT37 and 10 ng/ml BDNF.
Mouse mixed and astrocyte-free neuronal culture experiments.
Cortical mouse mixed cultures of neurons and astrocytes were prepared as
described38 from E17.5 Nrf2þ /þ and Nrf2/ mice with Neurobasal growth
medium supplemented with B27 (Invitrogen). Typically, these cultures areB90%
NeuN-positive neurons and 10% GFAP-positive astrocytes.39 To obtain astrocyte-
free neuronal preparations (498% NeuNþ neurons and o0.2% GFAPþ
astrocytes15), cultures were treated with antimitotic cytosine-arabinoside imme-
diately post-plating. Experiments were carried out on cultured neurons following a
period of 10 days during which cortical neurons develop a network of processes,
express functional NMDA-type and AMPA/kainate-type glutamate receptors, and
form synaptic contacts. CDDOTFEA-induced neuroprotection against oxidative
insults was studied as described previously for 3H-1,2-dithiole-3-thione-induced
protection.35 Before the start of experiments, cultures were placed in minimal
medium in the presence or absence of CDDOTFEA (100 nM), 16 h before an
oxidative insult was applied in the form of H2O2 (100mM, stabilised solution; Sigma).
Cultures were fixed 24 h later and analysed after DAPI staining; cell death
was quantified by counting (blind) the number of apoptotic nuclei as a percentage of
the total. Approximately 1500 cells were counted per treatment, across four
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independent experiments. Morphologically, H2O2-treated neurons show typical
signs of apoptotic-like cell death (shrunken cell body and large round
chromatin clumps).
Gene expression analysis. Total RNA was isolated via the Absolutely RNA
miniprep kit, cDNA synthesis performed via the AffinityScript cDNA (Stratagene,
Stockport, UK) synthesis kit using oligo-dT and random hexamer primers, and qRT-
PCR performed using Brilliant SYBR Green master mix (Stratagene), following the
manufacturer’s instructions. RT-PCRs were run over 28 cycles, and PCR products
were separated on a 1.6% agarose in TBE gel, with GelRed for DNA visualisation.
Primer sequences are listed in Supplementary Table S1.
Immunohistochemistry. Cells plated on glass coverslips were fixed with 4%
paraformaldehyde for 20 min at room temperature and washed three times with
PBS. Samples were next blocked for 1 h at room temperature with 0.2% Triton/PBS/
5% goat serum and then incubated overnight with primary antibody in 0.2% Triton/
PBS/2% goat serum at 41C. After three washes in PBS, secondary antibody
(Alexa Fluor, 1 : 1000) in PBS/DAPI (1 : 4000) was next applied for 1 h at room
temperature. Primary antibodies used included Nestin (1 : 300; Chemicon, Bedford,
MA, USA), 3CB2 (1 : 5; Developmental Studies Hybridoma Bank (DSHB), Iowa City,
IA, USA), GFAP (1 : 300; Dako; 1 : 500; Abcam, Cambridge, UK), S100b (1 : 300;
Dako, Ely, UK), AQP4 (1 : 50; Santa Cruz, Santa Cruz, CA, USA), EAAT1 (1 : 200;
Novus Biologicals, Cambridge, UK), TuJ1 (1 : 500; Sigma-Aldrich) and activated
caspase-3 (1 : 50; Chemicon).
Glutathione determination. Intracellular glutathione content was measured
by the MCB (Sigma) assay. MCB is non-fluorescent in its native state and
fluorescent upon conjugation with thiol-containing molecules including glutathione.
While the MCB assay does not exclude other thiol-containing molecules in addition
to glutathione, quantification of fluorescence has been used successfully to quantify
GSH content.27 Cells were incubated in minimal medium containing 50 mM MCB for
45 min. Medium was removed and the cells were lysed; cell membranes were
pelleted by centrifugation at (15 000 r.p.m., 5 min), and the fluorescence of the
supernatant read by plate reader (FLUOstar OPTIMA, BMG Labtech, Aylesbury,
UK) (excitation 405 nm/emission 520 nm). Fluorescence values obtained were
adjusted for background signal and normalised to protein concentration, determined
by BCA absorbance assay using bovine serum albumin standards.
Glutamate uptake. Plated astrocytes were washed twice in Tissue Buffer
(5 mM Tris, 320 mM sucrose, pH 7.4) and then exposed to 10 mM 3H-glutamate in
either Naþ -containing Krebs buffer (120 mM NaCl, 25 mM NaHCO3, 5 mM KCl,
2 mM CaCl2, 1 mM KH2PO4, 1 mM MgSO4, 10% glucose) or Na
þ -free Krebs
(120 mM choline-Cl and 25 mM Tris-HCl, pH 7.4 substituted for NaCl and NaHCO3,
respectively) for 10 min at 371C. Uptake was stopped by placing the astrocytes back
on ice and washing them twice with Wash Buffer (5 mM Tris/160 mM NaCl pH 7.4).
Cells were lysed with 0.1 M NaOH and radioactivity measured using a scintillation
counter. Naþ -dependent uptake was determined by subtracting Naþ -free counts
from total counts in the presence of Naþ.
GCL enzyme kinetic assay. Reaction buffer and lysis buffer were prepared
as described previously.40 ATP and cysteine hydrochloride were prepared fresh.
Cells were lysed in 350ml of lysis buffer, and cell debris pelleted (13 000 r.p.m.,
10 min). In all, 50ml of cell lysate was placed at 371C for each of five time points, and
50ml of reaction buffer and 40 mM ATP added. After 5 min equilibration, 50 ml
20 mM cysteine hydrochloride was added, for 30, 20, 10, and 5 min, and at time 0.
The reaction was terminated by the addition of 50 ml metaphosphoric acid, and
placement on ice. Precipitated proteins were pelleted (2500 r.p.m., 5 min), and
glutamyl-cysteine quantified by NDA fluorescence. In all, 20 ml of reaction mixture
was combined with 180ml of NDA reaction mixture, comprising 140ml Trizma-base
50 mM, 20ml 1 M NaOH, 20ml NDA 10 mM, and fluorescence determined by plate
reader (excitation 485 nm/emission 520 nm).
Conditioned medium generation. Astrocytes were treated with minimal
medium, consisting of Salt–Glucose–Glycine39 supplemented with 10% MEM
(Invitrogen), in the presence and absence of drugs for 6 h, after which the drugs
were washed out and fresh minimal medium replaced. Drugs included 1[2-Cyano-
3,12-dioxool-eana-1,9(11)-dien-28-oyl] trifluoroethylamide (CDDOTFEA; 250 nM),
BSO (200mM), and bischloronitrosurea (BCNU; 50 mM). After 24 h, ACM was
removed, cell debris pelleted (41C, 3400 r.p.m. for 10 min), and half-supplemented
with fresh minimal medium before the addition of H2O2 and neuronal viability
determined.
Neuronal injury and cell viability assays. Neurons were preconditioned
in minimal medium for 12 h, before addition of control or astrocyte-conditioned
minimal medium supplemented with H2O2. After peroxidative challenge, cell viability
was quantified using CellTiter-Glo Luminescent Cell Viability Assay (Promega,
Madison, WI, USA), following the manufacturer’s instructions. In brief, assay
reagents were reconstituted according to instructions, and an equal volume added
to cell medium. After 10 min, cell lysate was removed and luminescence quantified
by plate reader.
Data analysis. All experiments were performed with at least three biological
repeats; within each, three technical repeats were generated. Experiments were
repeated across two independent HESC lines. qPCR data were normalised to
GAPDH. For quantitative IHC, five random views were taken per coverslip, and cell
counts were performed manually, assessing staining specificity and morphology.
Data are presented as mean±standard error of the mean; statistical analyses were
performed in Microsoft Excel and GraphPad Prism 5 (GraphPad Software, Inc., San
Diego, CA, USA) by univariate and two-way ANOVA with Newman–Keuls post-test
and the Students’ t-test. A P-value of 0.05 was considered statistically significant.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. We thank Professor Michael Sporn for the gift of
CDDOTFEA, Professor Jeff Johnson for comments on the manuscript, and Professor
Masayuki Yamamoto of the University of Tsukuba (now University of Tohoku) for
kindly providing Nrf2/ mice. TT and JDH wish to thank the Association for
International Cancer Research for their support (Grant 07-0074). This work was
funded by the Evelyn Trust, Motor Neuron Disease Association, Medical Research
Council, and the Wellcome Trust.
1. Di Giorgio F, Boulting G, Bobrowicz S, Eggan K. Human embryonic stem cell-derived motor
neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell
Stem Cell 2008; 3: 637–648.
2. Marchetto M, Muotri A, Mu Y, Smith A, Cezar G, Gage F. Non-cell-autonomous effect of
human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem
cells. Cell Stem Cell 2008; 3: 649–657.
3. Zhang S, Wernig M, Duncan I, Brustle O, Thomson J. In vitro differentiation of
transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 2001;
19: 1129–1133.
4. Krencik R, Weick JP, Liu Y, Zhang ZJ, Zhang SC. Specification of transplantable astroglial
subtypes from human pluripotent stem cells. Nat Biotechnol 2011; 29: 528–534.
5. Joannides A, Webber D, Raineteau O, Kelly C, Irvine K, Watts C et al. Environmental
signals regulate lineage choice and temporal maturation of neural stem cells from human
embryonic stem cells. Brain 2007; 130 (Part 5): 1263–1275.
6. Molne M, Studer L, Tabar V, Ting Y, Eiden M, McKay R. Early cortical precursors do not
undergo LIF-mediated astrocytic differentiation. J Neurosci Res 2000; 59: 301–311.
7. Naka H, Nakamura S, Shimazaki T, Okano H. Requirement for COUP-TFI and II in the
temporal specification of neural stem cells in CNS development. Nat Neurosci 2008; 11:
1014–1023.
8. Barnabe-Heider F, Wasylnka JA, Fernandes KJ, Porsche C, Sendtner M, Kaplan DR et al.
Evidence that embryonic neurons regulate the onset of cortical gliogenesis via
cardiotrophin-1. Neuron 2005; 48: 253–265.
9. Yanagisawa M, Nakashima K, Takizawa T, Ochiai W, Arakawa H, Taga T. Signaling
crosstalk underlying synergistic induction of astrocyte differentiation by BMPs and IL-6
family of cytokines. FEBS Lett 2001; 489: 139–143.
10. Nakashima K, Yanagisawa M, Arakawa H, Kimura N, Hisatsune T, Kawabata M et al.
Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science
1999; 284: 479–482.
11. Andersen J. Oxidative stress in neurodegeneration: cause or consequence? Nat Med
2004; 10(Suppl): S18–S25.
12. Vargas MR, Johnson JA. The Nrf2-ARE cytoprotective pathway in astrocytes. Expert Rev
Mol Med 2009; 11: e17.
13. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses
via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47: 89–116.
14. McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation
of transcription factor Nrf2 contributes to the negative regulation of antioxidant response
element-driven gene expression. J Biol Chem 2003; 278: 21592–21600.
HESC-derived astrocytes mediate non-cell-autonomous neuroprotection
K Gupta et al
786
Cell Death and Differentiation
15. Bell KF, Al-Mubarak B, Fowler JH, Baxter PS, Gupta K, Tsujita T et al. Mild oxidative stress
activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning.
Proc Natl Acad Sci USA 2011; 108: E1–E2; author reply E3–E4.
16. Haskew-Layton RE, Payappilly JB, Smirnova NA, Ma TC, Chan KK, Murphy TH et al.
Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from
oxidative stress via an Nrf2-independent pathway. Proc Natl Acad Sci USA 2010; 107:
17385–17390.
17. Vargas M, Johnson D, Sirkis D, Messing A, Johnson J. Nrf2 activation in astrocytes
protects against neurodegeneration in mouse models of familial amyotrophic lateral
sclerosis. J Neurosci 2008; 28: 13574–13581.
18. Shih A, Johnson D, Wong G, Kraft A, Jiang L, Erb H et al. Coordinate regulation of
glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons
from oxidative stress. J Neurosci 2003; 23: 3394–3406.
19. Chen P, Vargas M, Pani A, Smeyne R, Johnson D, Kan Y et al. Nrf2-mediated
neuroprotection in the MPTP mouse model of Parkinson’s disease: critical role for the
astrocyte. Proc Natl Acad Sci USA 2009; 106: 2933–2938.
20. Oberheim NA, Takano T, Han X, He W, Lin JH, Wang F et al. Uniquely hominid features of
adult human astrocytes. J Neurosci 2009; 29: 3276–3287.
21. Joannides A, Fiore-Heriche C, Battersby A, Athauda-Arachchi P, Bouhon I, Williams L et al.
A scaleable and defined system for generating neural stem cells from human embryonic
stem cells. Stem Cells 2007; 25: 731–737.
22. Koch P, Opitz T, Steinbeck J, Ladewig J, Brustle O. A rosette-type, self-renewing human
ES cell-derived neural stem cell with potential for in vitro instruction and synaptic
integration. Proc Natl Acad Sci USA 2009; 106: 3225–3230.
23. Rothstein J, Martin L, Levey A, Dykes-Hoberg M, Jin L, Wu D et al. Localization of neuronal
and glial glutamate transporters. Neuron 1994; 13: 713–725.
24. Mahesh VB, Dhandapani KM, Brann DW. Role of astrocytes in reproduction and
neuroprotection. Mol Cell Endocrinol 2006; 246: 1–9.
25. Stack C, Ho D, Wille E, Calingasan N, Williams C, Liby K et al. Triterpenoids CDDO-ethyl
amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain
pathology in a transgenic mouse model of Huntington’s disease. Free Radic Biol Med
2010; 49: 147–158.
26. Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T et al. Pharmacodynamic
characterization of chemopreventive triterpenoids as exceptionally potent inducers of
Nrf2-regulated genes. Mol Cancer Ther 2007; 6: 154–162.
27. Barhoumi R, Bailey R, Burghardt R. Kinetic analysis of glutathione in anchored cells with
monochlorobimane. Cytometry 1995; 19: 226–234.
28. Barres BA. The mystery and magic of glia: a perspective on their roles in health and
disease. Neuron 2008; 60: 430–440.
29. Hampton D, Webber D, Bilican B, Goedert M, Spillantini M, Chandran S. Cell-mediated
neuroprotection in a mouse model of human tauopathy. J Neurosci 2010; 30: 9973–9983.
30. Lepore A, Rauck B, Dejea C, Pardo A, Rao M, Rothstein J et al. Focal transplantation-
based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat
Neurosci 2008; 11: 1294–1301.
31. Bolanos JP, Heales SJ, Peuchen S, Barker JE, Land JM, Clark JB. Nitric oxide-mediated
mitochondrial damage: a potential neuroprotective role for glutathione. Free Radic Biol
Med 1996; 21: 995–1001.
32. Garcia-Estrada J, Garcia-Segura L, Torres-Aleman I. Expression of insulin-like growth
factor I by astrocytes in response to injury. Brain Res 1992; 592: 343–347.
33. Dringen R, Pfeiffer B, Hamprecht B. Synthesis of the antioxidant glutathione in neurons:
supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 1999; 19:
562–569.
34. Gegg ME, Beltran B, Salas-Pino S, Bolanos JP, Clark JB, Moncada S et al. Differential
effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and
neurones: implications for neuroprotection/neurodegeneration? J Neurochem 2003; 86:
228–237.
35. Soriano FX, Leveille F, Papadia S, Higgins LG, Varley J, Baxter P et al. Induction of
sulfiredoxin expression and reduction of peroxiredoxin hyperoxidation by the
neuroprotective Nrf2 activator 3H-1,2-dithiole-3-thione. J Neurochem 2008; 107:
533–543.
36. Vallier L, Pedersen R. Differentiation of human embryonic stem cells in adherent and in
chemically defined culture conditions. Curr Protoc Stem Cell Biol 2008; Chapter 1: Unit
1D.4.1–1D.4.7.
37. Borghese L, Dolezalova D, Opitz T, Haupt S, Leinhaas A, Steinfarz B et al. Inhibition of
notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase
transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells 2010; 28:
955–964.
38. Leveille F, Papadia S, Fricker M, Bell KF, Soriano FX, Martel MA et al. Suppression of the
intrinsic apoptosis pathway by synaptic activity. J Neurosci 2010; 30: 2623–2635.
39. Papadia S, Soriano FX, Leveille F, Martel MA, Dakin KA, Hansen HH et al. Synaptic
NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 2008; 11:
476–487.
40. White CC, Viernes H, Krejsa CM, Botta D, Kavanagh TJ. Fluorescence-based microtiter
plate assay for glutamate-cysteine ligase activity. Anal Biochem 2003; 318: 175–180.
This work is licensed under the Creative Commons
Attribution-NonCommercial-No Derivative Works 3.0
Unported License. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/3.0
Supplementary Information accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)
HESC-derived astrocytes mediate non-cell-autonomous neuroprotection
K Gupta et al
787
Cell Death and Differentiation
